Search research articles
Contact Us
Filters
Showing results (71-80 of 100) with videos related to
Page
of 10
Sort By:
Breast Cancer Research and Treatment
|
May 10, 2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)
Diep Ho, Jessica Huang, Judith-Anne W Chapman, et al.
European Journal of Haematology
|
May 30, 2021
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Bethany E Monteith, Christopher P Venner, Matthew C Cheung, et al.
The New England Journal of Medicine
|
October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Blood
|
June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
Ming Han, Alli Murugesan, Nizar J Bahlis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Marie Plante, Sven Mahner, Alexandra Sebastianelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
Sarah E Ferguson, Lori A Brotto, Janice Kwon, et al.
Journal of the National Cancer Institute
|
April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12
Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Biopreservation and Biobanking
|
March 14, 2014
A framework for biobank sustainability
Peter H Watson, Sara Y Nussbeck, Candace Carter, et al.
Blood
|
June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 100) with videos related to
Sort By:
Page
of 10
Breast Cancer Research and Treatment
|
May 10, 2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)
Diep Ho, Jessica Huang, Judith-Anne W Chapman, et al.
European Journal of Haematology
|
May 30, 2021
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Bethany E Monteith, Christopher P Venner, Matthew C Cheung, et al.
The New England Journal of Medicine
|
October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Blood
|
June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
Ming Han, Alli Murugesan, Nizar J Bahlis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Marie Plante, Sven Mahner, Alexandra Sebastianelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
Sarah E Ferguson, Lori A Brotto, Janice Kwon, et al.
Journal of the National Cancer Institute
|
April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12
Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Biopreservation and Biobanking
|
March 14, 2014
A framework for biobank sustainability
Peter H Watson, Sara Y Nussbeck, Candace Carter, et al.
Blood
|
June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
Page
of 10